Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The findings on orforglipron come from ATTAIN-MAINTAIN, a first-of-its-kind phase 3 trial conducted by the GLP-1 drugmaker Eli Lilly, which manufactures Zepbound and is developing the new oral medication
Also known as End-Stage Renal Disease, serious kidney disease has a lot of issues associated with it
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for the Treatment of Obesity in People With Type 2 Diabetes (ATTAIN-2): A Phase 3, Double-Blind, Randomised, Multicentre, Placebo-Controlled Trial
Most patients see more significant results after 8-12 weeks as the dosage is gradually increased
US$ 25.80
US$ 22.62
US$ 25.94
US$ 23.54
US$ 29.63
US$ 28.94
US$ 25.70
